Mancardi GL, Sardanelli F, Parodi RC, et al. 1998. Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. Neurology, 50:1127–33. Martin R, Sturzebecher CS, McFarland HF. 2001. Immunotherapy of multiple sclerosis: where are we? Where should we go? Nat Immunol, 2:785–8. Miller A, Shapiro S, Gershtein R, et al. 1998. Treatment of MS with Copolymer-I (Copaxone):implicating mechanism of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol, 92:113–21. Munari L, Lovati R, Boiko A. 2004. Therapy with glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev, 1:CD004678. Neuhaus O, Farina C, Wekerle H, et al. 2001. Mechanisms of action of GA in MS. Neurology, 56:702–8. Neuhaus O, Archelos JJ, Hartung H-P. 2003. Immunomodulation in MS: from immunosuppression to neuroprotection. Trends Pharmacol Sci, 24:131–8. Petereit HF, Lindemann H, Schoppe S. 2003. Effect of immunomodulatory drugs on in vitro production of brain-derived neurotrophic factor. Mult Scler, 9:16–20. Prat A, Biernacki K, Antel JP. 2005. Th1 and Th2 lymphocyte migration across the human BBB is specifically regulated by interferon beta and copolymer-1. J Autoimmun, 24:119–24. Rauschka H, Farina C, Sator P, et al. 2005. Severe anaphylactic reaction to glatiramer acetate with specific IgE. Neurology, 64:1481–2. Rovaris M, Comi G, Rocca M, et al; the European/Canadian Glatiramer Acetate Study Group. 2001. Short-term brain volume change in relapsing-remitting multiple sclerosis:effect of glatiramer acetate and implications. Brain, 124:1803–12. Sormani MP, Rovaris M, Valasina P, et al. 2004. Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. Neurology, 62:1432–4. Teitelbaum D, Meshorer A, Hirshfeld T, et al. 1971. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol, 1:242–8.. Glatiramer for MS Thoenen H. 1995. Neurotrophins and neuronal plasticity. Science, 279:593–8. Trapp BD, Peterson J, Ransohoff RM, et al. 1998. Axonal transaction in the lesions of multiple sclerosis. N Engl J Med, 338:278–85. van Waesberghe JH, van Walderveen MA, Castelijns JA, et al. 1998. Patterns of lesion development in multiple sclerosis; longitudinal observations with T1-weighted spin echo and MTR. AJNR Am J Neuroradiol, 19:675–83. Wolinsky JS. 2004a. Glatiramer acetate for the treatment of multiple sclerosis. Expert Opin Pharmacother, 5:875–91. Wolinsky JS. 2004b. The PROMiSe trial:baseline data review and progress report. Mult Scler, 10(Suppl 1):S65–72. Wolinsky JS, Comi G, Filippi M, et al; the European/Canadian GA Study Group. 2002. Copaxone’s effect on MRI-monitored disease in relapsing MS is reproducible and sustained. Neurology, 59:1284–6. Wolinsky JS, Narayana PA, Johnson KP; the Copolymer I Multiple Sclerosis Study Group and the MRI Analysis Center. 2001. United States open- label GA extension trial for relapsing MS: MRI and clinical correlates. Mult Scler, 7:33–41. Wolinsky JS, Pardo L, Stark Y et al; the PROMISE study group. 2004. Effect of GA on primary progressive MS: initial analysis of the completed PROMISE trial. Neurology, 62(Suppl 5):A97–98. Yan Q, Elliott J, Snider WD. 2002. Brain-derived neurotrophic factors rescues spinal motor neurons from axotomy-induced cell death. Nature, 360:753–5. Yong VW. 2002. Differential mechanisms of action of interferon-B and GA in MS. Neurology, 59:802–8. Yousry TA, Major EO, Ryschkewitsch C, et al. 2006. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med, 354:924–33. Ziemssen T, Kumpfel T, Klinkert WEF, et al. 2002. Glatiramer acetate- specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain, 125:2381–91. international Journal of Nanomedicine 2006:1(3) 289